The U.S. Department of Defense has released detailed instructions for a new mandatory testosterone deficiency screening policy targeting active-duty and reserve service members aged 30 and above. This policy follows an announcement made in July by U.S. Secretary of Defense Pete Hegseth. The guidance, effective immediately, introduces standardized screening and treatment protocols for both male and female service members to enhance military readiness by addressing hormonal and energy-related issues.
Hegseth, an advocate for testosterone use, introduced the mandate last month, sparking debates among experts regarding the scientific rationale behind such a directive. The U.S. Food and Drug Administration is set to convene a panel of experts in mid-September to deliberate on the medical application of testosterone.
Under the new guidelines, men aged 30 and older will undergo compulsory testosterone blood tests, while younger men will be tested upon request or if healthcare providers detect warning signs. For women, routine testosterone blood tests are not mandated, but screening for fatigue and irregular menstrual cycles, which could indicate hormonal imbalances and conditions like low-energy availability and relative energy deficiency in sport, is advised.
The guidance also outlines criteria for prescribing off-label testosterone to women, particularly postmenopausal women experiencing significantly diminished sexual desire. Concerns have been raised by medical professionals about the potential risks of widespread testosterone testing, with some cautioning against unnecessary or potentially harmful treatments. They argue that there is limited evidence to support the notion that universal screening for low testosterone levels among military personnel would enhance U.S. combat readiness.